ArticleThe Journal of experimental medicine1998
Inhibition of angiogenesis by interleukin 4.
Article in The Journal of experimental medicine, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 251 citations in OpenAlex.
- Pooled it
- Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.Cancer research · 2010Trial
- Inflammatory and Anti-Inflammatory Response of the Ocular Surface After Excimer Laser Treatment.Biomedicines · 2026Article
- Different Expression of Vascularization and Inflammatory Regulators in Cells Derived from Oral Mucosa and Limbus.Bioengineering (Basel, Switzerland) · 2025Article
- Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Reinventing type 2 immunity in cancer.Nature · 2025Review
- A Self-Activating IL-15 Chimeric Cytokine Receptor to Empower Cancer Immunotherapy.ImmunoTargets and therapy · 2024Article
- Interleukin 12 in the Acute Phase of the Immune Response after Excimer Laser Treatment.Journal of clinical medicine · 2023Article
- Could senescence phenotypes strike the balance to promote tumor dormancy?Cancer metastasis reviews · 2023Review
- Review
- Eosinophils and melanoma: Implications for immunotherapy.Pigment cell & melanoma research · 2022Review
- Review
- Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.Frontiers in immunology · 2021Review
- Regulation of adipose tissue inflammation and systemic metabolism in murine obesity by polymer implants loaded with lentiviral vectors encoding human interleukin-4.Biotechnology and bioengineering · 2020Article
- TGF-β suppresses type 2 immunity to cancer.Nature · 2020Article
- Role of IL-4 in bone marrow driven dysregulated angiogenesis and age-related macular degeneration.eLife · 2020Article
- Biomarkers for the Noninvasive Diagnosis of Endometriosis: State of the Art and Future Perspectives.International journal of molecular sciences · 2020Review
- Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment.Journal of Cancer · 2020Review
- The Impact of Immune Cells on the Skeletal Muscle Microenvironment During Cancer Cachexia.Frontiers in physiology · 2020Review
- IGFBP3 inhibits angiogenesis through intracellular regulation of THBS1 expression.American journal of cancer research · 2020Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth factor. IL-4 as well as IL-13 inhibited the migration of cultured bovine or human microvascular cells, showing unusual dose-response curves that were sharply stimulatory at a concentration of 0.01 ng/ml but inhibitory over a wide range of higher concentrations. Recombinant cytokine from mouse and from human worked equally well in vitro on bovine and human endothelial cells and in vivo in the rat, showing no species specificity. IL-4 was secreted at inhibitory levels by activated murine T helper (TH0) cells and by a line of carcinoma cells whose tumorigenicity is known to be inhibited by IL-4. Its ability to cause media conditioned by these cells to be antiangiogenic suggested that the antiangiogenic activity of IL-4 may play a role in normal physiology and contribute significantly to its demonstrated antitumor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.